Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Family Medicine | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Pathology | Pharmacy | Conference News

Back to Journal Articles

AHA: Cardiac Stem Cells Show Promise in Heart Failure

Last Updated: November 14, 2011.

 

Promising phase 1 trial results on their safety, efficacy in post-MI heart failure

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Cardiac stem cell infusion improves left ventricular function and reduces infarct size in a phase I trial in patients with post-myocardial infarction heart failure, according to a study published online Nov. 14 in The Lancet to coincide with presentation at the American Heart Association's Scientific Sessions 2011, held from Nov. 12 to 16 in Orlando, Fla.

MONDAY, Nov. 14 (HealthDay News) -- Cardiac stem cell (CSC) infusion improves left ventricular (LV) function and reduces infarct size in a phase I trial in patients with post-myocardial infarction (MI) heart failure, according to a study published online Nov. 14 in The Lancet to coincide with presentation at the American Heart Association's Scientific Sessions 2011, held from Nov. 12 to 16 in Orlando, Fla.

Roberto Bolli, M.D., from the University of Louisville in Kentucky, and colleagues investigated the safety and efficacy of treating 16 post-MI heart failure participants with CSCs, compared to seven untreated patients, in a two-stage trial. In stage A, participants with post-MI LV dysfunction (ejection fraction [EF], ≤40 percent) prior to coronary artery bypass grafting (CABG) were consecutively assigned to the treatment versus control groups. In stage B, participants were randomly assigned to the treatment versus to control groups. The trial was ongoing at the time of reporting.

The investigators found no CSC-related adverse effects. The LVEF in 14 patients, who were analyzed from the treatment group, increased from 30.3 to 38.5 percent before and four months post-infusion, respectively; but did not change significantly in control patients at four versus eight months post-CABG. Eight treated patients showed a more pronounced effect at one year, with an LVEF increase of 12.3 EF units from baseline. An average infarct size of 32.6 g was significantly reduced by 7.8 and 9.8 g at four months and one year, respectively, in seven treated patients who underwent cardiac magnetic resonance imaging.

"The present results provide a strong rationale for further studies of CSC treatment in patients with severe heart failure secondary to ischemic cardiomyopathy," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Copyright © 2011 HealthDay. All rights reserved.


Previous: Rivaroxaban Improves Acute Coronary Syndrome Outcomes Next: Researchers Develop Working Pituitary Gland in Mouse Model

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.